Researchers from Kyverna Therapeutics Inc. presented preclinical data for KYV-101, a first-in-class, fully human autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of patients with B-cell-driven neurologic autoimmune diseases, including multiple sclerosis and myasthenia gravis.
Tessellate Bio BV has announced it is collaborating with CMRI (Children’s Medical Research Institute) and Omico (Australian Genomic Cancer Medicine Centre) to advance the understanding of the prevalence of alternative lengthening of telomeres (ALT) across tumor types and the genetic factors involved.
Precision Biosciences Inc. has submitted its first clinical trial applications (CTAs) to initiate a phase I study evaluating PBGENE-HBV, an in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV).
Researchers from Paragon Therapeutics Inc. presented the preclinical characterization of ORKA-001 (PR-035), a novel half-life extended monoclonal antibody targeting the p19 subunit of IL-23, designed to treat chronic skin disorders such as plaque psoriasis.
The spread of drug-resistant bacteria is a global health concern and could once again become a leading cause of mortality. The World Health Organization has flagged carbapenem-resistant Acinetobacter baumannii (CRAB), which has a mortality rate of 25%-60%, as a top priority pathogen requiring innovative therapies for its management. Researchers from the HUN-REN Biological Research Centre in Hungary have published a paper in Cell in which they describe designing and developing phage cocktails that target the most prevalent CRAB strains within specific geographic regions by using phylogeographic analysis and mapping the pathogen’s genetic diversity.
Novartis AG is enlisting the help of Generate:Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick the targets, although the targets Generate has been working on are off limits. Generate will be responsible for creating the lead candidate, at which point Novartis will take over development.
Cancer Research Technology Ltd. and My-T Bio Ltd. have jointly developed biarylamide derivatives acting as membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase (PKMYT1) inhibitors with potential for the treatment of cancer.
Work at Axcynsis Therapeutics Pte. Ltd. has led to the creation of antibody-drug conjugates (ADCs) comprising antibodies covalently linked to ecteinascidin and lurbinectedin derivatives through a linker; they are reported to be useful for the treatment of cancer.
Vividion Therapeutics Inc. has patented 2-azaspiro[3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of cancer.
RSS
